Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOTHELL, WA--(Marketwire - Oct 19, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, reported in vivo dose-dependent efficacy with...
-
BOTHELL, WA--(Marketwire - Oct 17, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading oligonucleotide-based drug discovery and development company, announced today that it has entered into a...
-
BOTHELL, WA--(Marketwire - Sep 8, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it will present at the...
-
BOTHELL, WA--(Marketwire - Sep 7, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced organizational changes that...
-
BOTHELL, WA--(Marketwire - Sep 1, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and...
-
BOTHELL, WA--(Marketwire - Aug 11, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNA-based drug discovery and development company, today reported financial results for the second quarter...
-
BOTHELL, WA--(Marketwire - Aug 10, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNA-based drug discovery and development company, reported in vivo data demonstrating up to 2.5-fold...
-
BOTHELL, WA--(Marketwire - Jul 18, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that R. John Fletcher was...
-
BOTHELL, WA--(Marketwire - Jul 8, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, reported data demonstrating that its proprietary...
-
BOTHELL, WA--(Marketwire - Jun 9, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced the completion of dosing for Cohort 1 in...